A Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Triple-Negative Breast Cancer (MK-2870-011/TroFuse-011)
NCT06841354
This study is recruiting at 36 US sites in 20 states, according to its ClinicalTrials.gov record last updated .
Summary
Researchers want to know if sacituzumab tirumotecan given alone or with pembrolizumab can treat triple negative breast cancer (TNBC). The main goal of this study is to learn if people treated with sacituzumab tirumotecan alone or with pembrolizumab live longer overall or without the cancer growing or spreading compared to people treated with chemotherapy.
Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov
Conditions studied
- Triple Negative Breast Neoplasms
Eligibility basics and study details
- Study type
- Interventional
- Phase
- Phase 3
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Sponsor
- Merck Sharp & Dohme LLC
- Last updated on ClinicalTrials.gov
- October 13, 2026
These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.
US recruiting sites
Alabama · 1
- USA Mitchell Cancer Institute ( Site 0090) · Mobile, AL
Arizona · 1
- Ironwood Cancer & Research Centers ( Site 0036) · Chandler, AZ
California · 4
- City of Hope ( Site 0097) · Duarte, CA
- City of Hope Lennar Foundation Cancer Center ( Site 0099) · Irvine, CA
- UCLA Department of Medicine - Hematology & Oncology ( Site 0047) · Los Angeles, CA
- UCSF Helen Diller Family Comprehensive Cancer Center ( Site 0016) · San Francisco, CA
District of Columbia · 1
- Washington Hospital Center ( Site 0098) · Washington D.C., DC
Florida · 3
- AdventHealth Medical Group Oncology and Hematology at Altamonte ( Site 0007) · Altamonte Springs, FL
- Orlando Health Cancer Institute ( Site 0012) · Orlando, FL
- Florida Cancer Specialists - East ( Site 7000) · West Palm Beach, FL
Georgia · 1
- University Cancer & Blood Center, LLC ( Site 0023) · Athens, GA
Idaho · 1
- St. Luke's Cancer Institute: Boise ( Site 0037) · Boise, ID
Illinois · 1
- University of Illinois Cancer Center ( Site 0044) · Chicago, IL
Maryland · 5
- MedStar Franklin Square Medical Center ( Site 0031) · Baltimore, MD
- MedStar Good Samaritan Hospital ( Site 0079) · Baltimore, MD
- MedStar Southern Maryland Hospital Center ( Site 0100) · Clinton, MD
- MedStar Montgomery Medical Center ( Site 0078) · Olney, MD
- Holy Cross Hospital ( Site 0091) · Silver Spring, MD
Michigan · 1
- Cancer & Hematology Centers of Western Michigan ( Site 0026) · Grand Rapids, MI
Mississippi · 1
- Hattiesburg Clinic Hematology/Oncology ( Site 0104) · Hattiesburg, MS
Nevada · 2
- Comprehensive Cancer Centers of Nevada ( Site 0015) · Las Vegas, NV
- Renown Regional Medical Center ( Site 0005) · Reno, NV
New Jersey · 1
- John Theurer Cancer Center at Hackensack University Medical Center ( Site 0082) · Hackensack, NJ
New Mexico · 1
- New Mexico Oncology Hematology Consultants Ltd. ( Site 0019) · Albuquerque, NM
New York · 2
- Perlmutter Cancer Center at NYU Langone Hospital - Long Island ( Site 0073) · Mineola, NY
- Laura and Isaac Perlmutter Cancer Center ( Site 0003) · New York, NY
Tennessee · 2
- SCRI Oncology Partners ( Site 7004) · Nashville, TN
- Tennessee Oncology ( Site 0018) · Nashville, TN
Texas · 5
- Texas Oncology - DFW ( Site 8007) · Dallas, TX
- Texas Oncology - West Texas ( Site 8004) · El Paso, TX
- Kelsey-Seybold Clinic - North Houston Campus ( Site 0096) · Houston, TX
- Kelsey-Seybold Clinic ( Site 0040) · Houston, TX
- Texas Oncology - San Antonio ( Site 8001) · San Antonio, TX
Utah · 1
- University of Utah, Huntsman Cancer Institute ( Site 0056) · Salt Lake City, UT
Virginia · 1
- Virginia Oncology Associates (VOA) ( Site 8002) · Norfolk, VA
Washington · 1
- Fred Hutchinson Cancer Center ( Site 0042) · Seattle, WA
Source: ClinicalTrials.gov, data processed . Recruiting US sites filtered by distance and site status; summaries shortened.